Clinical Trial

A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a prospective, single-arm, Phase Ib/II clinical study to evaluate the safety and efficacy of nimotuzumab combined with adebrelimab and chemotherapy in patients with recurrent and metastatic head and neck squamous cell carcinoma who are ineligible to high-dose cisplatin treatment.
Trial Details
NCT Number NCT07105592
Lead Sponsor Fudan University
Conditions Head and Neck Squamous Cell Carcinoma
Enrollment 68 participants
Start Date 2025-05-13
Primary Completion 2027-05-31 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-06